Clinical Trial Update: A Study to Evaluate IMC-002 in Neuromyelitis Optica Spectrum Disorder (NMOSD) Patients [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update describes an early-phase (Phase 1/2) study evaluating IMC-002 in neuromyelitis optica spectrum disorder, with the study status not ye…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuromyelitis Optica Spectrum Disorder

Drugs mentioned

• IMC-002

Snippet

Sponsor: ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd. | Conditions: Neuromyelitis Optica Spectrum Disorder (NMOSD) | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING